Condition
Peroxisomal Disorders
Total Trials
5
Recruiting
0
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Completed4
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02171104Phase 2Active Not Recruiting
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
NCT03163771CompletedPrimary
Evaluation of a New Strategy for the Diagnosis of Peroxisomal Diseases
NCT00007020Phase 3Completed
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
NCT00004348Completed
Study of Protein Translocation in Patients With Beta-Oxidation Disorders
NCT01043640Phase 2Completed
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Showing all 5 trials